MATINAS BIOPHARMA HOLDINGS, INC. Lease Obligation Incurred
MATINAS BIOPHARMA HOLDINGS, INC. (MTNB) reported Lease Obligation Incurred of $155.43 thousand for the 12-month period ending 2018-12-31, per its 10-K filed 2020-03-09.
Discontinued › Cash Flow › Other Cash Flow Items
us-gaap:CapitalLeaseObligationsIncurred · last filed 2020-03-09
- MATINAS BIOPHARMA HOLDINGS, INC. lease obligation incurred for the quarter ending 2018-12-31 was $7.49K, a 78.90% decline year-over-year.
- MATINAS BIOPHARMA HOLDINGS, INC. lease obligation incurred for the quarter ending 2018-09-30 was $66.87K.
- MATINAS BIOPHARMA HOLDINGS, INC. lease obligation incurred for the quarter ending 2018-06-30 was -$19.00.
- MATINAS BIOPHARMA HOLDINGS, INC. lease obligation incurred for the quarter ending 2018-03-31 was $81.09K.
- MATINAS BIOPHARMA HOLDINGS, INC. lease obligation incurred for fiscal 2018 was $155.43K, a 81.96% increase from fiscal 2017.
- MATINAS BIOPHARMA HOLDINGS, INC. lease obligation incurred for fiscal 2017 was $85.42K, a 174.98% increase from fiscal 2016.
- MATINAS BIOPHARMA HOLDINGS, INC. lease obligation incurred for fiscal 2016 was $31.06K.
- MATINAS BIOPHARMA HOLDINGS, INC. lease obligation incurred for fiscal 2015 was $0.00.
| Period end | Lease Obligation Incurred 3 month | Lease Obligation Incurred 6 month | Lease Obligation Incurred 9 month | Lease Obligation Incurred 12 month |
|---|---|---|---|---|
| 2018-12-31 | $7.49K derived: 10-K 12 month − 10-Q 9 month · filed 2020-03-09 | $74.36K derived: sum of 2 quarters · filed 2020-03-09 | $74.34K derived: sum of 3 quarters · filed 2020-03-09 | $155.43K 10-K · filed 2020-03-09 |
| 2018-09-30 | $66.87K derived: 10-Q 9 month − 10-Q 6 month · filed 2019-11-13 | $66.85K derived: sum of 2 quarters · filed 2019-11-13 | $147.94K 10-Q · filed 2019-11-13 | $183.43K derived: sum of 4 quarters · filed 2019-11-13 |
| 2018-06-30 | -$19.00 derived: 10-Q 6 month − 10-Q 3 month · filed 2019-08-13 | $81.07K 10-Q · filed 2019-08-13 | $116.56K derived: sum of 3 quarters · filed 2019-08-13 | $116.56K derived: sum of 4 quarters · filed 2019-08-13 |
| 2018-03-31 | $81.09K 10-Q · filed 2019-05-13 | $116.57K derived: sum of 2 quarters · filed 2019-05-13 | $116.57K derived: sum of 3 quarters · filed 2019-05-13 | |
| 2017-12-31 | $35.48K derived: 10-K 12 month − 10-Q 9 month · filed 2019-04-01 | $35.48K derived: sum of 2 quarters · filed 2019-04-01 | $85.42K 10-K · filed 2019-04-01 | |
| 2017-09-30 | $0.00 derived: 10-Q 9 month − 10-Q 6 month · filed 2018-11-09 | $49.94K 10-Q · filed 2018-11-09 | ||
| 2017-06-30 | $49.94K 10-Q · filed 2018-08-09 | |||
| 2016-12-31 | $0.00 derived: 10-K 12 month − 10-Q 9 month · filed 2018-03-16 | $0.00 derived: sum of 2 quarters · filed 2018-03-16 | $31.06K 10-K · filed 2018-03-16 | |
| 2016-09-30 | $0.00 derived: 10-Q 9 month − 10-Q 6 month · filed 2017-11-14 | $31.06K 10-Q · filed 2017-11-14 | ||
| 2016-06-30 | $31.06K 10-Q · filed 2017-08-08 | |||
| 2015-12-31 | $0.00 derived: 10-K 12 month − 10-Q 9 month · filed 2017-03-31 | $0.00 10-K · filed 2017-03-31 | ||
| 2015-09-30 | $0.00 10-Q · filed 2016-11-14 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Petros Pharmaceuticals, Inc. (PTPI) | United States | $0.003B | |
| ZyVersa Therapeutics, Inc. (ZVSA) | United States | $0.002B | |
| GeoVax Labs, Inc. (GOVX) | United States | $0.003B | -0.45 |
| BioXcel Therapeutics, Inc. (BTAI) | United States | $0.002B | |
| Silo Pharma, Inc. (SILO) | United States | $0.003B | -1.57 |
| JUPITER NEUROSCIENCES, INC. (JUNS) | United States | $0.002B | -0.02 |
| Genprex, Inc. (GNPX) | United States | $0.003B | -0.02 |
| Alaunos Therapeutics, Inc. (TCRT) | United States | $0.003B | -1.44 |
| ORAGENICS INC (OGEN) | United States | $0.002B | |
| Nexentis Technologies Inc. (NXTS) | $0.002B |